CD36: A multiligand molecule

Laboratory Hematology

Volumn 11, Issue 1, 2005, Pages 31-37

  Ge, Yimin ^a   Elghetany, M Tarek ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

CD36; Granulocytes; Leukemia; Thrombospondin receptor

Indexed keywords

CD36 ANTIGEN; LIGAND; THROMBOSPONDIN 1;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; AFRICAN AMERICAN; ANGIOGENESIS; ANTIGEN EXPRESSION; ASIAN; ATHEROSCLEROSIS; BLAST CELL; BRAIN MALARIA; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; ERYTHROLEUKEMIA; ETHNIC GROUP; HOST RESISTANCE; HUMAN; INSULIN RESISTANCE; MALIGNANT NEOPLASTIC DISEASE; PLASMODIUM FALCIPARUM; REGULATORY MECHANISM; REVIEW; SICKLE CELL CRISIS; TUMOR VASCULARIZATION;

ANTIGENS, CD; ANTIGENS, CD36; BLAST CRISIS; ETHNIC GROUPS; GENE EXPRESSION REGULATION; HUMANS; LEUKEMIA; MALARIA; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 15944371540     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: 10.1532/LH96.04056     Document Type: Review

References (70)

1. Li YS, Shyy YJ, Wright JG, Valente AJ, et al. The expression of monocyte chemotactic protein (MCP-1) in human vascular endothelium in vitro and in vivo. Mol Cell Biochem. 1993;126:61-68.
2. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001; 108:785-91.
3. Silverstein RL, Febbraio M. CD36 and atherosclerosis. Curr Opin Lipidol. 2000;11:483-491.
4. Fernandez-Ruiz E, Armesilla AL, Sanchez-Madrid F, et al. Gene encoding the collagen type I and thrombospondin receptor CD36 is located on chromosome 7q11.2. Genomics. 1993;17:759-761.
5. Greenwalt DE, Lipsky RH, Ockenhouse CF, et al. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood. 1992;80:1105-1115.
6. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188:1359-1368.
7. Ryeom SW, Sparrow JR, Silverstein RL. CD36 participates in the phagocytosis of rod outer segments by retinal pigment epithelium. J Cell Sci. 1996;109:387-395.
8. Swerlick RA, Lee KH, Wick TM, et al. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol. 1992;148:78-83.
9. Saving KL, Mankin PE, Gorman MJ. Differences in adhesion receptor expression between immature and older platelets and red cells of neonates and adults. J Pediatr Hematol Oncol. 2002;24: 120-124.
10. Kiefer CR, Snyder LM. Oxidation and erythrocyte senescence. Curr Opin Hematol. 2000;7:113-116.
11. Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998;93:229-240.
12. Chawla A, Barak Y, Nagy L, et al. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001;7:48-52.
13. Han J, Hajjar DP, Tauras JM, et al. Transforming growth factor-beta1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. J Biol Chem. 2000;275:1241-1246.
14. Feng J, Han J, Pearce SF, et al. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-β. J Lipid Res. 2000;41:688-696.
15. Sfeir Z, Ibrahimi A, Amri E, et al. Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport. Prostaglandins Leukot Essent Fatty Acids 1997;57:17-21.
16. Ikeda H, Mitani T, Ohnuma M, et al. A new platelet-specific antigen, Naka, involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang. 1989;57:213-217.
17. Curtis BR, Aster RH. Incidence of the Nak(a)-negative platelet phenotype in African Americans is similar to that of Asians. Transfusion. 1996;36:331-334.
18. Yamamoto N, Akamatsu N, Sakuraba H, et al. Platelet glycoprotein IV (CD36) deficiency is associated with the absence (type I) or the presence of (type II) of glycoprotein IV on monocytes. Blood 1994;83:392-397.
19. Imai M, Tanaka T, Kintaka T, et al. Genomic heterogeneity of type II CD36 deficiency. Clin Chim Acta. 2002;321:97-106.
20. Toba K, Hanawa H, Watanabe K, et al. Erythroid involvement in CD36 deficiency. Exp Hematol. 2001;29:1194-1200.
21. Lee K, Godeau B, Fromont P, et al. CD36 deficiency is frequent and can cause platelet immunization in Africans. Transfusion 1999;39:873-879.
22. Kankirawatana S, Kupatawintu P, Juji T, et al. Neonatal alloimmune thrombocytopenia due to anti-Nak(a). Transfusion. 2001;41:375-377.
23. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol. 1994;88:816-825.
24. Rock G, Chauhan K, Jamieson GA, et al. Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. Br J Haematol. 1994;88:878-880.
25. Lee K, Gane P, Roudot-Thoraval F, et al. The nonexpression of CD36 on reticulocytes and mature red cells does not modify the clinical course of patients with sickle cell anemia. Blood. 2001; 98:966-971.
26. Serghides L, Nathoo S, Walmsley S, et al. CD36 deficiency induced by antiretroviral therapy. AIDS. 2002;16:353-358.
27. Salat A, Bogingbauer G, Boehm D, et al. Changes of platelet surface antigens in patients suffering from abdominal septic shock. Thromb Res. 1999;95:289-294.
28. Elghetany MT, Alter BP, Patel J, et al. Aberrant CD36 expression on bone marrow granulocytes is a potential marker for inherited bone marrow failure syndromes, including Shwachman-Diamond syndrome [abstract]. In: Proceedings of the XVIth International Symposium on Technological Innovations in Laboratory Hematology; May 14-18, 2003; Orlando, Florida, USA.
29. Maynadie M, Picard F, Husson B, et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood. 2002; 100:2349-2356.
30. Rutella S, Rumi C, Puggioni P, et al. Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination. Haematologica. 1999;84:419-424.
31. Valet G, Repp R, Link H, et al. Pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters. Cytometry. 2003;53B:4-10.
32. Casasnovas RO, Slimane FK, Garand R, et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia. 2003;17:515-527.
33. Casasnovas RO, Campos L, Mugneret F, et al. Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphocytic leukemia subtypes: a prospective study of 432 patients. Leukemia. 1998;12:34-43.
34. Salah-Uddin H, Gordon MJ, Ford I, et al. Surface expression of fatty acid translocase (FAT/CD36) on platelets in myeloproliferative disorders and non-insulin dependent diabetes mellitus: effect on arachidonic acid uptake. Mol Cell Biochem. 2002; 239:203-211.
35. Murphy SC, Breman JG. Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and complications of pregnancy. Am J Trop Med Hyg. 2001;64(suppl 1-2):57-67.
36. Udomsangpetch R, Reinhardt PH, Schollaardt T, et al. Promiscuity of clinical Plasmodium falciparum isolates for multiple adhesion molecules under flow conditions. J Immunol. 1997;158:4358-4364.
37. World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94(suppl 1):S1-S90.
38. Yipp BG, Baruch DI, Brady C, et al. Recombinant PfEMP1 peptide inhibits and reverses cytoadherence of clinical Plasmodium falciparum isolates in vivo. Blood. 2003;101:331-337.
39. Traore B, Muanza K, Looareesuwan S, et al. Cytoadherence characteristics of Plasmodium falciparum isolates in Thailand using an in vitro human lung endothelial cells model. Am J Trop Med Hyg. 2000;62:38-44.
40. Aitman TJ, Cooper LD, Norsworthy PJ, et al. Malaria susceptibility and CD36 mutation. Nature. 2000;405:1015-1016.
41. Silamut K, Phu NH, Whitty C, et al. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol. 1999;155:395-410.
42. Serghides L, Smith TG, Patel SN, et al. CD36 and malaria: friends or foes? Trends Parasitol. 2003;19:461-469.
43. Endemann G, Stanton LW, Madden KS, et al. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993;268: 11811-11816.
44. Nicholson AC, Frieda S, Pearce A, et al. Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines: evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler Thromb Vasc Biol. 1995;15:269-275.
45. Boullier A, Gillotte KL, Horkko S, et al. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem. 2000;275:9163-9169.
46. Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000;105: 1095-1098.
47. Kunjathoor VV, Febbraio M, Podrez EA, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002;277:49982-49988.
48. Podrez EA, Schmitt D, Hoff HF, et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547-1560.
49. Febbraio M, Abumrad NA, Hajjar DP, et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999;274:19055-19062.
50. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049-1056.
51. Nakata A, Nakagawa Y, Nishida M, et al. CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipidladen macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol. 1999;19:1333-1339.
52. Nozaki S, Kashiwagi H, Yamashita S, et al. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest. 1995;96:1859-1865.
53. Febbraio M, Guy E, Coburn C, et al. The impact of overexpression and deficiency of fatty acid translocase (FAT)/CD36. Mol Cell Biochem. 2002;239:193-197.
54. Bonen A, Dyck DJ, Ibrahimi A, et al. Muscle contractile activity increases fatty acid metabolism and transport and FAT/CD36. Am J Physiol Endocrinol Metab. 1999;276:E642-649.
55. Coburn CT, Knapp FF Jr, Febbraio M, et al. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J Biol Chem. 2000;275:32523-32529.
56. Ibrahimi A, Sfeir Z, Magharaie H, et al. Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport. Proc Natl Acad Sci U S A. 1996;93:2646-2651.
57. Aitman TJ, Glazier AM, Wallace CA, et al. Identification of CD36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet. 1999;21:76-83.
58. Hajri T, Ibrahimi A, Coburn CT, et al. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem. 2001;276:23661-23666.
59. Pravenec M, Landa V, Zidek V, et al. Transgenic rescue of defective CD36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat Genet. 2001;27:156-158.
60. Gotoda T, Iizuka Y, Yamada N. Complex connection between CD36 and atherosclerosis, lipid metabolism, and insulin resistance syndromes. Curr Atheroscler Rep. 2000;2:453-454.
61. Watanabe K, Toba K, Ogawa Y, et al. Hypertrophic cardiomyopathy with type I CD36 deficiency. Jpn Circ J. 1998;62:541-542.
62. Adams JC, Tucker RP. The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development. Dev Dyn. 2000;218:280-299.
63. Tolsma SS, Stack MS, Bouck N. Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thrombospondin-1. Microvasc Res. 1997;54:13-26.
64. Lawler J, Sunday M, Thibert V, et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest. 1998;101:982-992.
65. Dawson DW, Pearce SF, Zhong R, et al. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. 1997;138:707-717.
66. Schuepp BJ, Pfister H, Clemetson KJ, et al. CD36-mediated signal transduction in human monocytes by anti-CD36 antibodies but not by anti-thrombospondin antibodies recognizing cell membrane-bound thrombospondin. Biochem Biophys Res Commun. 1991;175:263-270.
67. Jimenez B, Volpert OV, Reiher F, et al. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. Oncogene. 2001;20:3443-3448.
68. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994;265:1582-1584.
69. Lawler J, Miao WM, Duquette M, et al. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol. 2001;159:1949-1956.
70. Dawson DW, Volpert OV, Pearce SF, et al. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol. 1999;55:332-338.